TALPHERA Enters Material Definitive Agreement on Jan 12
Ticker: TLPH · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1427925
| Field | Detail |
|---|---|
| Company | Talphera, Inc. (TLPH) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $8 m, $116.5 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action, regulatory-filing
TL;DR
**TALPHERA just signed a big deal, watch for details on what it means for their future.**
AI Summary
TALPHERA, INC. filed an 8-K on January 18, 2024, reporting an event that occurred on January 12, 2024, related to an "Entry into a Material Definitive Agreement." This filing indicates a significant new contract or partnership for the pharmaceutical company, which could impact its future revenue streams or operational costs. For investors, this matters because material agreements can be catalysts for growth or sources of new liabilities, directly affecting the company's financial outlook and stock valuation.
Why It Matters
This filing signals a potentially significant business development for TALPHERA, INC., which could lead to new revenue opportunities or strategic shifts, directly influencing the company's financial performance and stock price.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its financial impact, which could be positive or negative.
Analyst Insight
Investors should monitor TALPHERA, INC.'s future filings and press releases for specific details regarding the "Material Definitive Agreement" to assess its potential impact on the company's financials and strategic direction before making investment decisions.
Key Players & Entities
- TALPHERA, INC. (company) — the registrant filing the 8-K
- January 12, 2024 (date) — date of the earliest event reported
- January 18, 2024 (date) — date the 8-K was filed
- 001-35068 (other) — Commission File No.
- TLPH (other) — Trading Symbol for Common Stock
- The Nasdaq Global Market (other) — exchange where Common Stock is registered
Forward-Looking Statements
- TALPHERA, INC. will release further details about the material definitive agreement in a subsequent filing or press release. (TALPHERA, INC.) — high confidence, target: Q1 2024
FAQ
What was the specific nature of the "Material Definitive Agreement" entered into by TALPHERA, INC. on January 12, 2024?
The filing states that TALPHERA, INC. entered into a "Material Definitive Agreement" on January 12, 2024, but it does not provide specific details about the nature of this agreement, such as the parties involved, the terms, or the financial implications.
Why did TALPHERA, INC. file this 8-K under Item 1.01 "Entry into a Material Definitive Agreement"?
TALPHERA, INC. filed this 8-K under Item 1.01 because SEC regulations require companies to disclose any material definitive agreement not made in the ordinary course of business, or any material amendment to such an agreement, that could significantly impact the company's financial condition or operations.
What is the trading symbol and the exchange where TALPHERA, INC.'s common stock is registered?
TALPHERA, INC.'s common stock has the trading symbol TLPH and is registered on The Nasdaq Global Market, as stated in the filing under "Securities registered pursuant to Section 12(b) of the Act."
When was TALPHERA, INC. formerly known as ACELRX PHARMACEUTICALS INC?
TALPHERA, INC. was formerly known as ACELRX PHARMACEUTICALS INC, and the date of its name change was February 22, 2008, according to the 'FORMER COMPANY' section of the filing.
What is the business address and phone number of TALPHERA, INC.?
TALPHERA, INC.'s business address is 1850 Gateway Drive, Suite 175, San Mateo, CA 94404, and its telephone number is (650) 216-3500, as listed in the 'BUSINESS ADDRESS' section of the filing.
Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 15.8 · Accepted 2024-01-18 08:35:16
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar
- $8 m — by the Company to XOMA, in exchange for $8 million, of the Company's right, title an
- $116.5 million — sales-based milestone payments of up to $116.5 million in respect of net sales of the Product,
Filing Documents
- acrx20240117_8k.htm (8-K) — 25KB
- 0001437749-24-001579.txt ( ) — 154KB
- tlph-20240112.xsd (EX-101.SCH) — 3KB
- tlph-20240112_def.xml (EX-101.DEF) — 11KB
- tlph-20240112_lab.xml (EX-101.LAB) — 15KB
- tlph-20240112_pre.xml (EX-101.PRE) — 11KB
- acrx20240117_8k_htm.xml (XML) — 2KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       Date: January 18, 2024 TALPHERA, INC.        By:   /s/ Raffi Asadorian       Raffi Asadorian       Chief Financial Officer